Trial · NCT03386825
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients with a DoT to Stivarga of more than 4 months versus total study sample | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | |
| Primary | ECOG performance status (0, 1) | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | ECOG: Eastern Cooperative Oncology Group |
| Primary | Primary site of disease | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | Rectum, Left-sided colon, Right-sided colon, Colon and rectum, Transverse, Unknown (in colon) |
| Primary | Tumor resection (yes, no, unknown) | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | |
| Primary | Specific site of metastasis | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | Lung, Liver, Bone, Extraregional nodes, Peritoneum, Multiple, Unknown |
| Primary | KRAS mutation (yes, no, unknown) | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | |
| Primary | RAS mutation (yes, no, unknown) | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | |
| Primary | BRAF mutation (yes, no, unknown) | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | |
| Secondary | Start date of Stivarga treatment | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | |
| Secondary | Number of prior treatment lines for metastatic cancer larger than 3 (yes, no, unknown) | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | |
| Secondary | Reason for discontinuation of Stivarga treatment | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | progression - symptomatic, Progression - radiological, Progression - radiological + symptomatic, Progression - unknown, Intolerability, Death, other, unknown, not applicable |
| Secondary | Subsequent mCRC treatment | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | Chemotherapy IV, Chemotherapy oral, Biologic therapy, Chemotherapy + biologic therapy, BSC, Other, Unknown, Not applicable |
| Secondary | Last daily Stivarga dose | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 | 80 mg, 120 mg, 160 mg, other, unknown |
| Secondary | Duration of treatment (months) | Retrospective chart review from 1-Jul-2015 to 1-Dec-2017 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03386825/registered